WO2022156404A1 - Composé de benzimidazole, son procédé de préparation et son application dans la préparation d'un inhibiteur de la ferroptose - Google Patents

Composé de benzimidazole, son procédé de préparation et son application dans la préparation d'un inhibiteur de la ferroptose Download PDF

Info

Publication number
WO2022156404A1
WO2022156404A1 PCT/CN2021/136185 CN2021136185W WO2022156404A1 WO 2022156404 A1 WO2022156404 A1 WO 2022156404A1 CN 2021136185 W CN2021136185 W CN 2021136185W WO 2022156404 A1 WO2022156404 A1 WO 2022156404A1
Authority
WO
WIPO (PCT)
Prior art keywords
reaction
och
preparation
conditions
ferroptosis
Prior art date
Application number
PCT/CN2021/136185
Other languages
English (en)
Chinese (zh)
Inventor
顾琼
徐峻
房玉影
Original Assignee
中山大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中山大学 filed Critical 中山大学
Publication of WO2022156404A1 publication Critical patent/WO2022156404A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the invention relates to the field of medicinal chemistry, in particular to a benzimidazole compound, a preparation method thereof, and an application in the preparation of a ferroptosis inhibitor.
  • Ferroptosis is a new type of non-apoptotic and regulated cell death discovered in recent years, characterized by iron-dependent accumulation of lipid ROS.
  • Glutathione peroxidase 4 GPX4
  • GPX4 Glutathione peroxidase 4
  • GPX4 is a key ferroptosis inhibitory protein in the ferroptosis pathway, which uses reduced glutathione as a cofactor to convert toxic lipid hydroperoxides. Reduced to non-toxic lipid alcohols. But when GPX4 is inactivated, intracellular lipid hydroperoxides accumulate in large quantities, thereby inducing ferroptosis.
  • Cysteine is a key raw material for the synthesis of reduced glutathione, and the source of intracellular cysteine depends on the glutamate/cystine antiporter system x c - .
  • the extracellular cystine is taken up by cells into the cell under the mediation of system x c - and then reduced to cysteine.
  • Inhibition of system x c - causes cysteine depletion, inhibits glutathione synthesis, and thus indirectly inhibits GPX4 enzymatic activity, ultimately inducing ferroptosis. Therefore, direct inhibition of GPX4 enzymatic activity, GPX4 knockdown, or inhibition of system x c- can induce ferroptosis.
  • ferroptosis is closely related to the occurrence and development of various neurological diseases (such as neurodegenerative diseases (Parkinson's disease, Alzheimer's disease, Huntington's disease, etc.) and stroke, etc.)
  • Ferroptosis is expected to be an effective strategy to prevent or treat these diseases; and ferroptosis inhibitors have been reported to significantly inhibit Parkinson's disease, Huntington's disease, ischemic stroke and hemorrhagic stroke in pathological models such as Cell damage and death.
  • ferroptosis inhibitors only radical-trapping antioxidants (RTAs), lipoxygenase inhibitors, and acyl-CoA synthase long-chain family members 4 (acyl- CoA synthetase long chain family member 4, ACSL4) inhibitors, iron chelators and deuterated polyunsaturated fatty acids. Therefore, the development of novel ferroptosis inhibitors is urgently needed.
  • the object of the present invention is to overcome the defects or deficiencies that the existing ferroptosis inhibitors have less types and poor activity, and provide a benzimidazole compound.
  • the benzimidazole compounds provided by the present invention have good ferroptosis inhibitory activity by introducing a lipophilic group at the R 1 position and a specific group at the R 2 position, and can be used for preventing and treating nervous system diseases such as A lead compound in stroke.
  • Another object of the present invention is to provide a method for preparing the above-mentioned benzimidazole compounds.
  • Another object of the present invention is to provide the application of the above-mentioned benzimidazole compounds in the preparation of ferroptosis inhibitors.
  • the present invention provides the following technical solutions:
  • R is halogen, methyl, alkoxy, alkynyloxy or hydroxy
  • X is C or N.
  • the present invention synthesized a series of benzimidazole compounds (formula (I)) by introducing a lipophilic group at the R1 position.
  • the lipophilic group at the R 1 position includes the following four different cyclic aliphatic amine side chains: N-methylpiperazine, methylpiperidine, piperidine and morpholine, and the middle aromatic ring is a benzene ring or pyridine ;
  • Determination of the inhibitory activity of this series of benzimidazole compounds on ferroptosis shows that R 1 is When X is C, the inhibitory activity is the best; therefore, based on this, different groups are introduced at the R 2 position to obtain a series of benzimidazole compounds (such as formula (II)).
  • the benzimidazole compounds provided by the invention have good ferroptosis inhibitory activity, and can be used as a leading compound for preventing and treating nervous system diseases such as stroke.
  • the halogen is F or Cl.
  • the alkoxy group is -OCH 3 , -OCH 2 CH 3 , -OCH 2 CH 2 CH 3 or -OCH(CH 3 ) 2 .
  • the alkynyloxy group is -OCH 2 C ⁇ CH.
  • R is substituted at one or both of the 6, 7 or 8 positions.
  • R when R is substituted at the 6-position, R is -F, -Cl, -OCH 3 , -OH, -OCH 2 CH 3 , -OCH 2 CH 2 CH 3 , -OCH(CH 3 ) 2 or - OCH 2 C ⁇ CH;
  • R is -CH 3 when R is substituted at the 7 position
  • R is -OCH 3 or -OH
  • R is substituted at the 6- and 7-positions, R is -OH or -OCH 3 .
  • R is -OH or -OCH 3 .
  • the present invention also provides a method for preparing the above-mentioned benzimidazole compounds.
  • the preparation method of above-mentioned benzimidazole compound comprises the steps:
  • the conditions of the coupling reaction in S11 are: basic conditions, and the reaction is carried out at 110° C. for 16 hours.
  • the reduction temperature in S12 is 60° C. and the time is 2 h.
  • the amide reaction in S13 is stirring at room temperature for 6 hours, and the subsequent ring-closing reaction is refluxing overnight under glacial acetic acid.
  • a mixture of dichloromethane and methanesulfonic acid is used as a solvent.
  • lithium aluminum hydride is used for reduction in S22.
  • the reaction is carried out at 80° C. for 24 hours.
  • the conditions of the amide reaction and the ring closure reaction in S25 are the same as those in S13.
  • the conditions of the coupling reaction in S31 are as follows: in an inert atmosphere, the reaction is carried out at 80° C. for 24 h or 16 h.
  • the conditions of the amide reaction and the ring closure reaction in S33 are the same as those in S13.
  • the use of the benzimidazole compounds in the preparation of ischemic stroke medicines is preferred.
  • the compounds provided by the present invention are tested for the activity of inhibiting ferroptosis by using Erastin to induce ferroptosis on HT22 cells, and it is found that the activity of compound 9a is the best.
  • 9a has significant inhibitory activity against ferroptosis induced by different types of ferroptosis inducers, and has inhibitory effects on two hallmark features of ferroptosis (lipid peroxidation and up-regulation of PTGS2 mRNA).
  • the present invention has the following advantages and effects:
  • the benzimidazole compounds provided by the invention have significant ferroptosis inhibitory activity, and the benzimidazole ferroptosis inhibitors have great application prospects in the prevention and treatment of nervous system diseases such as stroke;
  • the preparation method of the present invention has easily available raw materials and simple preparation.
  • Figure 1 shows the inhibitory effect of compound 9a on two features of ferroptosis (RSL3-induced lipid peroxidation and PTGS2 mRNA up-regulation);
  • FIG. 1 shows the TTC detection results.
  • the present invention is further explained below with reference to the embodiments and the accompanying drawings, but the embodiments do not limit the present invention in any form.
  • the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the technical field.
  • reaction formula 1 (a) potassium carbonate, N,N-dimethylformamide, 110°C, 16h; (b) nickel, hydrazine hydrate, methanol, 60°C, 2h; (c) 1.O-benzo Triazole-N,N,N',N'-tetramethylurea tetrafluoroborate, N,N-diisopropylethylamine, N,N-dimethylformamide, room temperature, 6h; 2 . Glacial acetic acid, reflux, overnight.
  • Triazole-N,N,N',N'-tetramethylurea tetrafluoroborate (385mg, 1.2mmol)
  • o-phenylenediamine derivatives 2a-2d (1.1mmol) were added , at room temperature for 6 hours.
  • the reaction was quenched with ice water, extracted with ethyl acetate, the organic layer was dried over anhydrous sodium sulfate, and spin-dried under reduced pressure; the solid obtained by spin-drying was dissolved in 10 mL of glacial acetic acid, and the reaction was refluxed overnight.
  • intermediates 7a-7i are hydrolyzed under alkaline conditions to obtain the intermediates 8a-8i, which are then reacted with the intermediate o-phenylenediamine derivative 2a through amide reaction and ring closure reaction, and finally the final products 9a-9k are obtained.
  • intermediates 5a-5b, 6a-6b, 7a and 7c were synthesized according to the conditions in our previous work.
  • reaction formula 2 (a) methanesulfonic acid, sodium azide, dichloromethane, room temperature, overnight; (b) lithium aluminum hydride, tetrahydrofuran, reflux, 4h; (c) potassium carbonate, cuprous iodide, L-proline, dimethyl sulfoxide, 80°C, 24h, nitrogen protection; (d) lithium hydroxide, tetrahydrofuran, 90°C, 3h; (e) 1.O-benzotriazole-N,N ,N',N'-tetramethylurea tetrafluoroborate, N,N-diisopropylethylamine, N,N-dimethylformamide, room temperature, 6h; 2. Glacial acetic acid, reflux, overnight . Compounds 9j and 9k were obtained by demethylation of compounds 9h and 9i under boron tribromide, respectively.
  • intermediate 7b was synthesized from 6-chloro-1,2,3,4-tetrahydroisoquinoline (5.03g, 30mmol) and ethyl 3-iodobenzoate (5.52g, 20mmol) according to the above method to obtain a white oil material (3.72 g, 59%).
  • intermediate 7d was synthesized from 1,2,3,4-tetrahydroisoquinolin-6-ol (4.48g, 30mmol) and ethyl 3-iodobenzoate (5.52g, 20mmol) according to the above method to obtain a white oil material (3.33 g, 56%).
  • intermediate 7g was synthesized from 1,2,3,4-tetrahydroisoquinolin-8-ol (4.48g, 30mmol) and ethyl 3-iodobenzoate (5.52g, 20mmol) according to the above method to obtain a white oil material (3.98 g, 67%).
  • reaction formula 3 (a) di-tert-butyl dicarbonate, 4-dimethylaminopyridine, tetrahydrofuran, room temperature, 0.5h; (b) sodium hydride, acetonitrile, 60°C, 24h; (c) 1. hydrochloric acid, 1 ,4-dioxane, room temperature, 3h; 2.
  • Potassium carbonate cuprous iodide, L-proline, dimethyl sulfoxide, 80°C, 24h, nitrogen protection;
  • reaction formula 4 (a) potassium carbonate, cuprous iodide, L-proline, dimethyl sulfoxide, 80°C, 24h; or sodium carbonate, tetrakistriphenylphosphonium palladium, 1,4-dioxane Hexacyclic/water, 80°C, 16h, nitrogen protection; (b) lithium hydroxide, tetrahydrofuran, 90°C, 3h; (c) 1.O-benzotriazole-N,N,N',N'- Tetramethylurea tetrafluoroborate, N,N-diisopropylethylamine, N,N-dimethylformamide, room temperature, 6h; 2. Glacial acetic acid, reflux, overnight.
  • 17b was synthesized from 16b and 2a as above as a white solid (40%).
  • 1 H NMR 400MHz, CD 3 OD
  • 17c was synthesized from 16c and 2a as above as a tan solid (44%).
  • 1 H NMR 400MHz, CD 3 OD
  • ⁇ 8.24 s, 1H
  • 7.54-7.49 m, 2H
  • 7.19 s, 1H
  • 7.18-7.16 m, 1H
  • 7.04(dd, J 8.8, 2.0Hz, 1H)
  • Example 2 Test of ferroptosis inhibitory activity of the compounds obtained in Example 1
  • HT22 cells mouse hippocampal neuron cells
  • DMEM high-glucose medium containing 10% fetal bovine serum and 1% double antibody at 37°C and 5% carbon dioxide concentration.
  • HT22 cells were seeded in a 96-well plate at 3000 cells/well, and after culturing for 24 hours, the original culture medium was removed by suction, 1 ⁇ M RSL3 ⁇ compound was added for 24 hours, and 10 ⁇ l CCK-8 solution was added to each well, and incubated at 37°C for 4 hours. , and the absorbance OD value was detected at a wavelength of 450 nm.
  • HT1080 cells human fibrosarcoma cells
  • MEM medium containing 10% fetal bovine serum and 1% double antibody at 37°C and 5% carbon dioxide concentration.
  • 50nM siRNA scramble and siRNA GPX4 were transferred into HT1080 cells with Lipofectamine TM 3000 reagent, respectively. Compounds were added after 12 hours, and the cells were harvested after incubation for 36 hours for qPCR and CCK-8 experiments.
  • the specific steps of the qPCR experiment are as follows: the cells to be treated were washed twice with PBS, the total RNA was extracted with RNAiso plus reagent, 1 ⁇ g of total RNA was reverse transcribed into cDNA using ReverTra Ace qPCR RT Master Mix, and then PCR was performed using SYBR Green Realtime PCR Master Mix. Amplification.
  • HT22 cells were seeded in 6-well plates at 3 ⁇ 10 4 cells/well for 24 hours, then 1 ⁇ M RSL3 ⁇ compound was added for 3 hours, and then incubated with 5 ⁇ M BODIPY-C11 probe at 37°C for half an hour. After cells were washed once with PBS, trypsinized, centrifuged and collected in 1 ml of PBS, the fluorescence intensity of the FL1 channel was detected by flow cytometry at 488 nm. At least 10,000 cells were detected per sample.
  • HT22 cells were seeded at 3000 cells/well in a 96-well plate and cultured for 24 hours, then 1 ⁇ M RSL3 ⁇ compound was added for 3 hours, and then 5 ⁇ M BODIPY-C11 probe and Hoechst 33342 (1 ⁇ g/ml) were used at 37°C After co-incubating for half an hour, the cells were washed once with PBS, and then photographed with a FV3000 laser confocal microscope (60 ⁇ ).
  • HT22 cells were seeded at 3 ⁇ 10 4 cells/well in 6-well plates and cultured for 24 hours, then added 1 ⁇ M RSL3 ⁇ compound for 12 hours, washed twice with PBS, extracted total RNA with RNAiso plus reagent, and used ReverTra Ace qPCR RT Master Mix 1 ⁇ g of total RNA was reverse transcribed into cDNA, and then used SYBR Green Realtime PCR Master Mix for PCR amplification.
  • compound 9a inhibited RSL3-induced ferroptosis in HT22 cells in a dose-dependent manner; compound 9a also inhibited the ferroptosis induced by GPX4 in HT1080 cells in a dose-dependent manner.
  • Activity live cell imaging results showed that compound 9a could significantly inhibit the increase of RSL3-induced lipid ROS, which was consistent with the results of flow cytometry.
  • compound 9a also had inhibitory activity on the increase of RSL3-induced cytoplasmic ROS; finally, compound 9a also had inhibitory activity. Concentration-dependently inhibited RSL3-induced upregulation of PTGS2 mRNA.
  • Example 4 Relief effect of compound 9a obtained in Example 1 on ischemia-reperfusion injury in vivo
  • Ischemic stroke is the most common form of stroke and one of the leading causes of death and permanent disability. So far, there is no effective treatment.
  • ferroptosis is involved in neuronal damage and death in the pathological process of ischemic stroke, and inhibition of ferroptosis can alleviate brain damage in vivo.
  • compound 9a has significant ferroptosis inhibitory activity on HT22 cells, we investigated whether this compound can protect SD rats from ischemia/reperfusion in the Middle Cerebral Artery Occlusion (MCAO) model nerve damage caused.
  • MCAO Middle Cerebral Artery Occlusion
  • the animals were randomly divided into 4 groups, namely blank control group, model control group, positive control group, and test sample 9a group, with 12 animals in each group.
  • Dosage test sample 9a 10 mg/kg, positive control drug edaravone 10 mg/kg; blank control group and model control group were given normal saline in the same way.
  • Dosing frequency once half an hour before the operation, once 2 hours after the operation; administration route: intraperitoneal injection, the volume is 5ml/kg.
  • the rats were anesthetized by intraperitoneal injection of 7% chloral hydrate 5ml/kg, the median neck incision was made, the left common carotid artery and external carotid artery were isolated and ligated, and the pterygofrontal artery was isolated.
  • the proximal end of the internal carotid artery is prepared, and the distal end is placed with an arterial clip.
  • An incision is made at the bifurcation of the common carotid artery, and a 4-0 nylon thread is inserted with a depth of 17 to 20 mm. , block all blood flow sources in the middle cerebral artery, let it be ischemia for 1.5h and then pull out the suture for about 1cm to achieve reperfusion.
  • the wound was disinfected with iodophor, and the skin was sutured. Then return to the cage.
  • the rest of the steps were the same as above, except that the line was not plugged in.
  • the results of TTC staining showed that compared with the model group, the cerebral infarct volume was significantly reduced and the behavior was more normal after 9a treatment, indicating that compound 9a can significantly alleviate ischemia/reperfusion-induced brain injury in vivo, and is expected to develop into a Lead compounds for the treatment of ischemic stroke.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Sont divulgués dans la présente invention un composé de benzimidazole, son procédé de préparation et son application dans la préparation d'un inhibiteur de la ferroptose. Le composé de benzimidazole a une structure telle que représentée dans la formule (I) ou la formule (II). Selon le composé de benzimidazole fourni par la présente invention, un groupe lipophile est introduit dans une position R1, et un groupe spécifique est introduit dans une position R2, de telle sorte que le composé obtenu présente une activité inhibitrice de la ferroptose relativement bonne et peut être utilisé en tant que composé principal pour la prévention et le traitement de maladies du système nerveux telles que l'accident vasculaire cérébral.
PCT/CN2021/136185 2021-01-25 2021-12-07 Composé de benzimidazole, son procédé de préparation et son application dans la préparation d'un inhibiteur de la ferroptose WO2022156404A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110097009.9A CN112939943B (zh) 2021-01-25 2021-01-25 一种苯并咪唑类化合物及其制备方法和在制备铁死亡抑制剂中的应用
CN202110097009.9 2021-01-25

Publications (1)

Publication Number Publication Date
WO2022156404A1 true WO2022156404A1 (fr) 2022-07-28

Family

ID=76236429

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/136185 WO2022156404A1 (fr) 2021-01-25 2021-12-07 Composé de benzimidazole, son procédé de préparation et son application dans la préparation d'un inhibiteur de la ferroptose

Country Status (2)

Country Link
CN (1) CN112939943B (fr)
WO (1) WO2022156404A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112939943B (zh) * 2021-01-25 2022-09-16 中山大学 一种苯并咪唑类化合物及其制备方法和在制备铁死亡抑制剂中的应用
CN115232074A (zh) * 2022-08-22 2022-10-25 湖南复瑞生物医药技术有限责任公司 一种1-烷基取代-2-甲基-5-溴苯并咪唑的合成方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056155A1 (fr) * 2005-11-03 2007-05-18 Chembridge Research Laboratories, Inc. Composes heterocycliques utiles comme modulateurs des tyrosine kinases
CN108484527A (zh) * 2018-04-27 2018-09-04 四川大学 一种10h-吩噻嗪类铁死亡抑制剂及其制备方法与应用
CN109879856A (zh) * 2018-12-17 2019-06-14 中山大学 一种多功能抗阿尔茨海默病的苯并咪唑衍生物及其制备方法和应用
CN111548345A (zh) * 2020-04-03 2020-08-18 中山大学 一类苯并咪唑类衍生物及其制备方法和应用
CN111574474A (zh) * 2019-02-19 2020-08-25 成都恒昊投资有限公司 一种抑制铁死亡的小分子化合物及其制备方法与应用
CN112939943A (zh) * 2021-01-25 2021-06-11 中山大学 一种苯并咪唑类化合物及其制备方法和在制备铁死亡抑制剂中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109232533A (zh) * 2017-09-28 2019-01-18 北京越之康泰生物医药科技有限公司 氮杂环类衍生物、其制备方法及其医药用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056155A1 (fr) * 2005-11-03 2007-05-18 Chembridge Research Laboratories, Inc. Composes heterocycliques utiles comme modulateurs des tyrosine kinases
US20080207635A1 (en) * 2005-11-03 2008-08-28 Alexey Vyacheslavovich Anikin Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
CN108484527A (zh) * 2018-04-27 2018-09-04 四川大学 一种10h-吩噻嗪类铁死亡抑制剂及其制备方法与应用
CN109879856A (zh) * 2018-12-17 2019-06-14 中山大学 一种多功能抗阿尔茨海默病的苯并咪唑衍生物及其制备方法和应用
CN111574474A (zh) * 2019-02-19 2020-08-25 成都恒昊投资有限公司 一种抑制铁死亡的小分子化合物及其制备方法与应用
CN111548345A (zh) * 2020-04-03 2020-08-18 中山大学 一类苯并咪唑类衍生物及其制备方法和应用
CN112939943A (zh) * 2021-01-25 2021-06-11 中山大学 一种苯并咪唑类化合物及其制备方法和在制备铁死亡抑制剂中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FANG YUYING, CHEN XIUCAI, TAN QINGYUN, ZHOU HUIHAO, XU JUN, GU QIONG: "Inhibiting Ferroptosis through Disrupting the NCOA4–FTH1 Interaction: A New Mechanism of Action", ACS CENTRAL SCIENCE, vol. 7, no. 6, 23 June 2021 (2021-06-23), pages 980 - 989, XP055952604, ISSN: 2374-7943, DOI: 10.1021/acscentsci.0c01592 *

Also Published As

Publication number Publication date
CN112939943A (zh) 2021-06-11
CN112939943B (zh) 2022-09-16

Similar Documents

Publication Publication Date Title
WO2022156404A1 (fr) Composé de benzimidazole, son procédé de préparation et son application dans la préparation d'un inhibiteur de la ferroptose
JP5840763B2 (ja) ブロモドメイン阻害剤として有用なテトラヒドロキノリン誘導体
CA2913840C (fr) Composes presentant une activite anti-cancereuse
CN106220644B (zh) 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用
CA2786957C (fr) Derives d'amidoacridine utiles comme inhibiteurs selectifs de la protease specifique a l'ubiquitine 7
JP2012530705A (ja) 二置換フタラジンヘッジホッグ経路アンタゴニスト
EP1554257A1 (fr) Derives de quinazolinone utilises comme agents anti-hyperalgesiques
WO2005053609A2 (fr) Methodes d'utilisation d'inhibiteurs de desacetylase nad+ dependante
WO2016112768A1 (fr) Inhibiteur des histone désacétylases de type benzofuroxan oxide, méthode de préparation et utilisation correspondantes
WO2024051720A1 (fr) Composé de 5-pyridine-1h-indazole pour l'inhibition ciblée de clk2 et utilisation du composé
KR100304177B1 (ko) (1,2,4)트리아졸로(4,3-a)퀴녹살린화합물,이의제조방법및이를함유하는약제학적조성물_
Young et al. 2-Arylindoles as gonadotropin releasing hormone (GnRH) antagonists: optimization of the tryptamine side chain
CA2819106C (fr) Inhibiteurs de kat ii
EP1587804A1 (fr) Antagonistes du recepteur des androgenes
TWI290554B (en) Process for preparation 5-(1-piperazinyl)-benzofuran-2-carboxamide by transition metal-catalyzed amination
CN111592530B (zh) 含醛肟的他克林衍生物类选择性丁酰胆碱酯酶抑制剂及其制备方法和应用
CN115286583B (zh) 一种含二苯基氨基嘧啶类化合物、制备及其作为HDACs酶抑制剂的应用
US20170174633A1 (en) Pyrazole compounds selective for neurotensin 2 receptor
RU2685501C1 (ru) Амидсодержащие производные 2-оксиндола, способ их получения и применения
JP2007511570A (ja) 不適切なａｌｋ５に関連する疾患を治療するための１−アミノ−イソキノリン誘導体
TW509679B (en) Substituted N-isoquinolinyl-benzamides, a process for the preparation thereof and pharmaceutical compositions comprising them
CN107793360B (zh) 吲哚胺2,3-双加氧酶抑制剂与应用
CN111205244A (zh) 噻唑并环类化合物、其制备方法、中间体和应用
CN114401935B (zh) 离子通道拮抗剂/阻断剂及其用途
CN116444499A (zh) 一种含4-喹唑啉酮的苯丙氨酸类衍生物及其制备方法与应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21920778

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21920778

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 21920778

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 24/01/2024)